Cheol-Kyu Park
Overview
Explore the profile of Cheol-Kyu Park including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
57
Citations
425
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Park C, Jun H, Oh H, Lee J, Cho H, Kim Y, et al.
Cells
. 2023 May;
12(9).
PMID: 37174645
This study aimed to investigate the feasibility of blood-based biomarkers, including blood tumor mutation burden (bTMB), to predict atezolizumab efficacy in relapsed and advanced non-small cell lung cancer (NSCLC). Stage...
12.
Park C, Oh H, Kim Y, Kim Y, Ahn S, Jeong W, et al.
J Thorac Oncol
. 2023 Apr;
18(8):1042-1054.
PMID: 37085032
Introduction: This study aimed to investigate real-world evidence for efficacy and safety of durvalumab consolidation (DC) after chemoradiotherapy (CRT) in patients with unresectable stage III NSCLC. Methods: Patients with stage...
13.
Park C, Oh I, Kim Y
Transl Lung Cancer Res
. 2023 Apr;
12(3):649-652.
PMID: 37057118
No abstract available.
14.
Park C, Jeon N, Park H, Oh H, Kim Y, Jeon H, et al.
Cancers (Basel)
. 2023 Mar;
15(5).
PMID: 36900397
This study aimed to add real-world evidence to the literature regarding the effectiveness and safety of durvalumab consolidation (DC) after concurrent chemoradiotherapy (CCRT) in the treatment of unresectable stage III...
15.
Park C, Lee S, Cho H, Oh H, Kim Y, Kim Y, et al.
Cancers (Basel)
. 2023 Feb;
15(4).
PMID: 36831494
We recruited 50 patients with unresectable stage III NSCLC who received CCRT between March 2020 and March 2021. Durvalumab consolidation (DC) was administered to patients ( = 23) without progression...
16.
Na Y, Park H, Lee J, Kho B, Kim T, Shin H, et al.
PLoS One
. 2022 Dec;
17(12):e0278610.
PMID: 36454973
Objective: Pulmonary arteriovenous malformation (PAVM) is a rare pulmonary disease. Although most patients with PAVMs are asymptomatic, cerebral complications associated with PAVMs are often fatal. This study aimed to evaluate...
17.
Park C, Oh H, Yoo S, Lee S, Lee S, Kim E, et al.
Transl Lung Cancer Res
. 2022 Sep;
11(8):1606-1618.
PMID: 36090637
Background: We aimed to evaluate the efficacy of postoperative adjuvant pemetrexed plus cisplatin (Pem-Cis) in pathologic stage IB-IIIA lung adenocarcinoma (LUAD) patients. Methods: A prospective, phase II study was performed...
18.
Lee J, Kim E, Park C, Lee S, Lee M, Yoon S, et al.
Cancer Res Treat
. 2022 Sep;
55(1):112-122.
PMID: 36049499
Purpose: Although osimertinib is the standard-of-care treatment of epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer, real-world evidence on the efficacy of osimertinib is not enough to...
19.
Park C, Oh I, Kim Y
Transl Cancer Res
. 2022 Feb;
8(2):346-349.
PMID: 35116765
No abstract available.
20.
Kim T, Jang T, Choi C, Kim M, Yong Lee S, Park C, et al.
Cancer Med
. 2021 Jul;
10(17):5809-5822.
PMID: 34258882
Objectives: The optimal sequence for the administration of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) for treating non-small cell lung cancer (NSCLC) is still unclear. This study aimed...